This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sala, C. Articles by Morganti, A. Search for Related Content PubMed PubMed Citation Articles by Sala, C. Articles by Morganti, A.

Blunted Vascular and Renal Effects of Exogenous Atrial Natriuretic Peptide in Patients with Cushing’s Disease

Istituto Clinica Medica (C.S., A.M.) and Istituto Scienze Endocrine (B.A.), Università di Milano and Ospedale Maggiore Istituto Ricovero e Cura a Carattere Scientifico, 20122 Milan, Italy

Address all correspondence and requests for reprints to: Carla Sala, M.D., Centro Fisiologia Clinica e Ipertensione-Policlinico, Via F. Sforza 35, 20122 Milan, Italy. E-mail: carla.sala{at}unimi.it

The role of atrial natriuretic peptide (ANP) in glucocorticoid hypertension is still controversial, as glucocorticoids enhance the secretion of ANP in vivo, but reduce its biological activity in vitro. In isolated cells, for example, the cGMP response to ANP is suppressed by dexamethasone. We tested the in vivo relevance of this observation by comparing the cGMP, endocrine, and renal responses to exogenous ANP in patients with Cushing’s disease (CD; n = 10) and in a matched group of essential hypertensives (EH; n = 8) and normotensive controls (N; n = 4). -human-ANP was infused at 0.01 µg/kg/min for 120 min with a 30-min recovery period; hormonal and arterial pressure measurements were performed at 30-min intervals, and renal parameters were measured at baseline and after infusion.

There was a 4-fold increase in plasma ANP in all groups, but the increments in plasma cGMP were about 50% lower in CD than in N and EH; urinary cGMP was similarly lower in CD (247 ± 61 vs. 529 ± 146 and 384 ± 54 nmol/150 min, respectively). This was associated with a reduced peak increase in hematocrit in CD (+2.6 ± 0.9%) compared with N (+6.6 ± 0.9%) and EH (+7.1 ± 0.7%; P < 0.05 CD vs. both); the diuretic and natriuretic effects of ANP were also lower in CD than in EH with very similar systemic pressure levels (382 ± 63 vs. 848 ± 130 mL/150 min, and 61 ± 14 vs. 113 ± 14 mmol/150 min, respectively; P < 0.05 for both).

The increments in plasma and urinary cGMP in response to physiological doses of ANP are thus blunted in CD patients compared with those in N and EH. This biochemical defect is associated with reduced capillary permeability and a lesser diuretic and natriuretic effect. These data are compatible with an impairment of the biological activity of ANP in glucocorticoid hypertension in humans.

This article has been cited by other articles:

				M. Hartmann, B. V. Skryabin, T. Muller, A. Gazinski, J. Schroter, B. Gassner, V. O. Nikolaev, M. Bunemann, and M. Kuhn Alternative Splicing of the Guanylyl Cyclase-A Receptor Modulates Atrial Natriuretic Peptide Signaling J. Biol. Chem., October 17, 2008; 283(42): 28313 - 28320. [Abstract] [Full Text] [PDF]

				P Haentjens, L De Meirleir, R Abs, J Verhelst, K Poppe, and B Velkeniers Glomerular filtration rate in patients with Cushing's disease: a matched case-control study Eur. J. Endocrinol., December 1, 2005; 153(6): 819 - 829. [Abstract] [Full Text] [PDF]

				M. Kuhn Structure, Regulation, and Function of Mammalian Membrane Guanylyl Cyclase Receptors, With a Focus on Guanylyl Cyclase-A Circ. Res., October 17, 2003; 93(8): 700 - 709. [Abstract] [Full Text] [PDF]